Fingolimod

Active ingredient: Fingolimod Hydrochloride

In short: Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

Forms & strengthsFingolimod Capsules are available as: 0.5 mg capsules are size “3” hard gelatin capsules having white opaque cap imprinted “0.5 mg” and white opaque body imprinted “MF” with black ink, filled with white to off white colored fine powder.
LabelApotex Corp.
Label updatedSep 14, 2026

What is Fingolimod used for?

Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

Fingolimod dosage

Cardiac Evaluation

Obtain a cardiac evaluation in patients with certain preexisting conditions .

Prior to starting treatment, determine whether patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction .

Complete Blood Count (CBC)

Review results of a recent CBC .

Serum Transaminases (ALT and AST) and Total Bilirubin Levels

Prior to starting treatment with Fingolimod Capsules (i.e., within 6 months), obtain serum transaminases [alanine transaminase (ALT) and aspartate transferase (AST)] and total bilirubin levels .

Ophthalmic Assessment

Obtain a baseline evaluation of the fundus, including the macula, near the start of the treatment with fingolimod capsules .

Skin Examination Obtain a baseline skin examination prior to or shortly after initiation of fingolimod capsules. If a suspicious skin lesion is observed, it should be promptly evaluated .

Prior Medications

If patients are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with Fingolimod Capsules .

Vaccinations

Test patients for antibodies to varicella zoster virus (VZV) before initiating Fingolimod Capsules; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with Fingolimod Capsules . It is recommended that pediatric patients if possible, complete all immunizations in accordance with current immunization guidelines prior to initiating Fingolimod Capsules therapy.

Patients who initiate Fingolimod Capsules, and those who reinitiate treatment after discontinuation for longer than 14 days, require first-dose monitoring. This monitoring is also recommended when the dose is increased in pediatric patients .

Fingolimod Capsules can be taken with or without food.

In adults and pediatric patients 10 years of age and older weighing more than 40 kg, the recommended dosage of Fingolimod Capsules is 0.5 mg orally once daily.

Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit.

Initiation of Fingolimod Capsules treatment results in a decrease in heart rate, for which monitoring is recommended . Prior to dosing and at the end of the observation period, obtain an electrocardiogram (ECG) in all patients.

First 6-Hour Monitoring

Administer the first dose of Fingolimod Capsules in a setting in which resources to appropriately manage symptomatic bradycardia are available. Monitor all patients for 6 hours after the first dose for signs and symptoms of bradycardia with hourly pulse and blood pressure measurement. …

How to take Fingolimod — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Tell patients not to discontinue Fingolimod Capsules without first discussing this with the prescribing healthcare provider. Advise patients to contact their healthcare provider if they accidently take more Fingolimod Capsules than prescribed.

Cardiac Effects

Advise patients that initiation of Fingolimod Capsules treatment results in a transient decrease in heart rate. Inform patients that they will need to be observed in the healthcare provider's office or other facility for at least 6 hours after the first dose, after reinitiation if treatment is interrupted or discontinued for certain periods, and after the dosage is increased .

Risk of Infections

Inform patients that they may have an increased risk of infections, some of which could be life-threatening, when taking Fingolimod Capsules, and that they should contact their healthcare provider if they develop symptoms of infection. Advise patients that the use of some vaccines should be avoided during treatment with Fingolimod Capsules and for 2 months after discontinuation. …

Warnings & precautions

Do not take this medicine if: Fingolimod Capsules are contraindicated in patients who have:

in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure

a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker

a baseline QTc interval ≥ 500 msec

cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs

had a hypersensitivity reaction to fingolimod or any of the excipients in Fingolimod Capsules. Observed reactions include rash, urticaria and angioedema upon treatment initiation .

Because of a risk for bradyarrhythmia and AV blocks, patients should be monitored during Fingolimod Capsules treatment initiation .

Reduction in Heart Rate

After the first dose of Fingolimod Capsules, the heart rate decrease starts within an hour. On Day 1, the maximum decline in heart rate generally occurs within 6 hours and recovers, although not to baseline levels, by 8 to 10 hours postdose. Because of physiological diurnal variation, there is a second period of heart rate decrease within 24 hours after the first dose. In some patients, heart rate decrease during the second period is more pronounced than the decrease observed in the first 6 hours. Heart rates below 40 bpm in adults, and below 50 bpm in pediatric patients occurred rarely. In controlled clinical trials in adult patients, adverse reactions of symptomatic bradycardia following the first dose were reported in 0.6% of patients receiving Fingolimod Capsules 0.5 mg and in 0.1% of patients on placebo. …

Fingolimod side effects

The following serious adverse reactions are described elsewhere in labeling:

Bradyarrhythmia and Atrioventricular Blocks

Infections

Progressive Multifocal Leukoencephalopathy

Macular Edema

Liver Injury

Posterior Reversible Encephalopathy Syndrome

Respiratory Effects

Fetal Risk

Severe Increase in Disability After Stopping Fingolimod Capsules

Tumefactive Multiple Sclerosis

Increased Blood Pressure

Malignancies

Immune System Effects Following Fingolimod Capsules Discontinuation

Hypersensitivity Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults

In clinical trials (Studies 1, 2, and 3), a total of 1,212 patients with relapsing forms of multiple sclerosis received Fingolimod Capsules 0.5 mg. This included 783 patients who received Fingolimod Capsules 0.5 mg in the 2-year placebo-controlled trials (Studies 1 and 3) and 429 patients who received Fingolimod Capsules 0.5 mg in the 1-year active-controlled trial (Study 2). The overall exposure in the controlled trials was equivalent to 1,716 person-years. Approximately 1,000 patients received at least 2 years of treatment with Fingolimod Capsules 0.5 mg. In all clinical studies, including uncontrolled extension studies, the exposure to Fingolimod Capsules 0.5 mg was approximately 4,119 person-years. …

Drug interactions

Fingolimod Capsules has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of Fingolimod Capsules treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility .

The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use Fingolimod Capsules and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is increased.

Fingolimod Capsules reduces the immune response to vaccination. Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with Fingolimod Capsules . Avoid the use of live attenuated vaccines during and for 2 months after treatment with Fingolimod Capsules because of the risk of infection. …

About this medicine

Fingolimod, USP is a sphingosine 1-phosphate receptor modulator.

Chemically, fingolimod, USP is 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride. Its structure is shown below:

Fingolimod hydrochloride, USP is a white to practically white powder that is freely soluble in water and in alcohol and soluble in propylene glycol. It has a molecular weight of 343.93 g/mol.

Fingolimod Capsules are provided as 0.5 mg hard gelatin capsules for oral use.

Each 0.5 mg capsule contains 0.56 mg of fingolimod hydrochloride, USP equivalent to 0.5 mg of fingolimod, USP.

Each Fingolimod Capsules 0.5 mg contains the following inactive ingredients: fumaric acid, stearic acid, pregelatinized starch and empty hard gelatin capsules.

The hard gelatin capsule shell contains gelatin, titanium dioxide, and is imprinted with black ink.

Black imprinting ink contains shellac, propylene glycol, black iron oxide and potassium hydroxide.

How it works: Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a545c6fc-7006-52c2-f476-34e9801ac04f. Read the full official label on DailyMed.